Ghent University Academic Bibliography

Journal Article
A1
open access

Glofitamab in relapsed/refractory mantle cell lymphoma : results from a phase I/II study

Tycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trneny, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner (UGent) , et al.

(2025) JOURNAL OF CLINICAL ONCOLOGY. 43(3). p.318-328

Add to list

Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL) : updated analysis from a phase 1/2 study

Tycel Phillips, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trneny, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner (UGent) , et al.

(2024) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 24(Supplement 1). p.S515-S516

Add to list

Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL) : updated analysis from a phase I/II study

Tycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trneny, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner (UGent) , et al.

(2024) JOURNAL OF CLINICAL ONCOLOGY. In Journal of Clinical Oncology 42(16, Supplement S).

Add to list

Glofitamab induces high response rates and durable remissions in patients (Pts) with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL), including those with a poor prognosis : subgroup results from a Phase I/II study

Tycel J. Phillips, Marek Trneny, Carmelo Carlo-Stella, Jan Maciej Zaucha, Tomasz Wrobel, Fritz Offner (UGent) , Michael J. Dickinson, Monica Tani, Michael Crump, Nancy L. Bartlett, et al.

(2024) BLOOD. In Blood 144(Supplement 1). p.1631-1633

Add to list

Englumafusp Alfa (CD19-4-1BBL) combined with glofitamab is safe and efficacious in patients with r/r B-NHL : extended follow up analysis of the dose-escalation part of Phase 1 Trial BP41072

Martin Hutchings, Michael J. Dickinson, Giuseppe Gritti, Carmelo Carlo-Stella, William Townsend, Francesc Bosch, Nancy L. Bartlett, Guillaume Cartron, Herve Ghesquieres, Roch Houot, et al.

(2024) BLOOD. In Blood 144(Supplement 1). p.991-992

Add to list

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma

Nicolas Leupin, Pier Luigi Zinzani, Franck Morschhauser, Stephane Dalle, Marie Maerevoet, Jean-Marie Michot, Vincent Ribrag, Fritz Offner (UGent) , Marie Beylot-Barry, Helene Moins-Teisserenc, et al.

(2022) CANCER. 128(5). p.1004-1014

Add to list

Glofitamab step-up dosing (SUD) : updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (Pts)

Carmelo Carlo-Stella, Cyrus Khan, Martin Hutchings, Fritz Offner (UGent) , Franck Morschhauser, Emmanuel Bachy, Michael Crump, Anna Sureda, Gloria Iacoboni, Corinne Haioun, et al.

(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 21(Supplement 1). p.S394-S394

Add to list

Journal Article
A1
open access

Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial

Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Carmelo Carlo-Stella, Fritz Offner (UGent) , Anna Sureda, Gilles Salles, Joaquin Martinez-Lopez, Michael Crump, Denise N. Thomas, et al.

(2021) JOURNAL OF CLINICAL ONCOLOGY. 39(18). p.1959-1971

Add to list

Journal Article
A1
open access

On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors

Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, Sylvie Rottey (UGent) , Simon A. J. Rule, David Cunningham, Frederic Peyrade, Christophe Fruchart, Hendrik-Tobias Arkenau, Isabelle Genvresse, et al.

(2020) MOLECULAR CANCER THERAPEUTICS. 19(2). p.468-478

Add to list

Phase 1 study of CD19 targeted 4-1BBL costimulatory agonist to enhance T cell (glofitamab combination) or NK cell effector function (obinutuzumab combination) in relapsed/refractory B cell lymphoma

Martin Hutchings, Fritz Offner (UGent) , Francesc Bosch, Giuseppe Gritti, Carmelo Carlo-Stella, Harriet Walter, William Townsend, Franck Morschhauser, Guillaume Cartron, Herve Ghesquieres, et al.

(2020) BLOOD. 136(Suppl. 1). p.16-17

Academic Bibliography

Glofitamab in relapsed/refractory mantle cell lymphoma : results from a phase I/II study

Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL) : updated analysis from a phase 1/2 study

Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL) : updated analysis from a phase I/II study

Glofitamab induces high response rates and durable remissions in patients (Pts) with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL), including those with a poor prognosis : subgroup results from a Phase I/II study

Englumafusp Alfa (CD19-4-1BBL) combined with glofitamab is safe and efficacious in patients with r/r B-NHL : extended follow up analysis of the dose-escalation part of Phase 1 Trial BP41072

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma

Glofitamab step-up dosing (SUD) : updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (Pts)

Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial

On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors

Phase 1 study of CD19 targeted 4-1BBL costimulatory agonist to enhance T cell (glofitamab combination) or NK cell effector function (obinutuzumab combination) in relapsed/refractory B cell lymphoma

Contents

Support

Contact